How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real‐world setting?

Lignende værker

• Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real‐world study
  af: Sullivan, Sean D., et al.
  Udgivet: (2019)
• Switching to insulin glargine 300 units/mL in real‐world older patients with type 2 diabetes (DELIVER 3)
  af: Bailey, Timothy S., et al.
  Udgivet: (2019)
• Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
  af: Bolli, Geremia B., et al.
  Udgivet: (2021)
• Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study
  af: Pettus, Jeremy, et al.
  Udgivet: (2019)
• Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study
  af: Escalada, Javier, et al.
  Udgivet: (2020)